Design, synthesis, and biological evaluation of coumarin derivatives against tuberculosis: a pharmacophore-based approach.

Rising cases of drug resistance tuberculosis including multidrug-resistant and extensively drug-resistant emphasize the need for development of drugs with novel mechanism of action. The study aimed to explore novel inhibitors targeting Mycobacterium thymidine monophosphate kinase (Mtb TMPK), a promising but unexplored drug target for tuberculosis treatment. A library of 200 coumarin derivatives was rationally designed and screened against Mtb TMPK, an essential enzyme in nucleotide biosynthesis of mycobacterium tuberculosis.

Structure-Guided Development of Mycobacterial Thymidine Monophosphate Kinase (MtbTMPK) Inhibitors: Unlocking New Frontiers in Tuberculosis Research.

Researchers are actively engaged in developing new antitubercular drugs targeting the enzyme Mycobacterial Thymidine Monophosphate Kinase (MtTMPK). This newer target has specificity and selectivity over other thymidylate kinases and especially differs from human thymidylate kinase (hTMPK). Over the last two decades, various potent MtTMPK inhibitors comprised of both nucleoside and non-nucleoside structures have been developed.

Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes.

Mitochondrial dysfunction plays a crucial role in the pathogenesis of various cardiac diseases, including heart failure, ischemic cardiomyopathy, and drug-induced cardiotoxicity. Mitochondria are essential for cellular energy production, calcium homeostasis, redox balance, and apoptotic regulation, making their proper function vital for cardiac health. Dysfunctional mitochondria contribute to excessive reactive oxygen species (ROS) production, impaired ATP synthesis, and disruption of mitochondrial dynamics, leading to cardiomyocyte damage and cell death.

Canagliflozin: A Comprehensive Review of Advances in Preclinical Research.

Canagliflozin is a synthetic sodium glucose transporter inhibitor (SGLT2i). It is the latest approved class of medicine used in the treatment of type 2 diabetes mellitus. As diabetes is emerging as the most common metabolic disorder, SGLT2i has lightened up the path of treatment with additional benefits.

Cardioprotective Potential of d-limonene against Isoproterenol induced Myocardial Infarction in Rats.

d-limonene is a type of colorless liquid hydrocarbon that falls under the category of cyclic monoterpene. It is the component found in the oil extracted from fruit peels. Isoproterenol, a synthetic β-adrenergic agonist, was administered to rats to induce myocardial injury by increasing heart rate and myocardial oxygen demand, leading to ischemia and oxidative stress.